Personality disorder medical therapy: Difference between revisions
Ayesha Anwar (talk | contribs) |
Ayesha Anwar (talk | contribs) |
||
| Line 7: | Line 7: | ||
==Medical Therapy== | ==Medical Therapy== | ||
No medical therapy is approved by [[Food and Drug administration]], FDA for treatment of personality disorders. [[Pharmacotherapy]] is utilised to manage symptoms during [[acute decompensation]] and trait vulnerabilities. | |||
Mood dysregulatory symptoms like emotional lability, anger outbursts, depressive crashes, and other affective dysregulation symptoms are managed with (selective serotonin reuptake inhibitors) SSRIs or [[selective norepinephrine reuptake inhibitors]] (SNRIs) like [[venlafaxine]]. Mood stabilizers like [[lithium]], [[valproate]], [[carbamazepine]], [[lamotrigine]] or [[topiramate]] are used as second line. | Mood dysregulatory symptoms like emotional lability, anger outbursts, depressive crashes, and other affective dysregulation symptoms are managed with (selective serotonin reuptake inhibitors) SSRIs or [[selective norepinephrine reuptake inhibitors]] (SNRIs) like [[venlafaxine]]. Mood stabilizers like [[lithium]], [[valproate]], [[carbamazepine]], [[lamotrigine]] or [[topiramate]] are used as second line. | ||
Impulse control dyscontrol symptoms are self-mutilation, aggression, eroticism, reckless sex, extravagant spending and uncontrolled substance use. They are managed with SSRIs as first line and [[monoamine oxidase inhibitors]] (MAOIs) as second line <ref name="urlpsychiatryonline.org">{{cite web |url=https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/bpd.pdf |title=psychiatryonline.org |format= |work= |accessdate=}}</ref>. British guidelines recommend against the use of medications for these symptoms <ref name="urlEuropean guidelines for personality disorders: past, present and future | Borderline Personality Disorder and Emotion Dysregulation | Full Text">{{cite web |url=https://bpded.biomedcentral.com/articles/10.1186/s40479-019-0106-3 |title=European guidelines for personality disorders: past, present and future | Borderline Personality Disorder and Emotion Dysregulation | Full Text |format= |work= |accessdate=}}</ref>. | Impulse control dyscontrol symptoms are self-mutilation, aggression, eroticism, reckless sex, extravagant spending and uncontrolled substance use. They are managed with SSRIs as first line and [[monoamine oxidase inhibitors]] (MAOIs) as second line <ref name="urlpsychiatryonline.org">{{cite web |url=https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/bpd.pdf |title=psychiatryonline.org |format= |work= |accessdate=}}</ref>. British guidelines recommend against the use of medications for these symptoms <ref name="urlEuropean guidelines for personality disorders: past, present and future | Borderline Personality Disorder and Emotion Dysregulation | Full Text">{{cite web |url=https://bpded.biomedcentral.com/articles/10.1186/s40479-019-0106-3 |title=European guidelines for personality disorders: past, present and future | Borderline Personality Disorder and Emotion Dysregulation | Full Text |format= |work= |accessdate=}}</ref>. | ||
Revision as of 17:38, 30 June 2021
|
Personality disorder Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Personality disorder medical therapy On the Web |
|
American Roentgen Ray Society Images of Personality disorder medical therapy |
|
Risk calculators and risk factors for Personality disorder medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Ayesha Anwar, M.B.B.S[2]
Overview
No medical therapy is approved by Food and Drug administration, FDA for treatment of personality disorders. Pharmacotherapy is utilised to manage symptoms during acute decompensation and trait vulnerabilities.
Medical Therapy
No medical therapy is approved by Food and Drug administration, FDA for treatment of personality disorders. Pharmacotherapy is utilised to manage symptoms during acute decompensation and trait vulnerabilities.
Mood dysregulatory symptoms like emotional lability, anger outbursts, depressive crashes, and other affective dysregulation symptoms are managed with (selective serotonin reuptake inhibitors) SSRIs or selective norepinephrine reuptake inhibitors (SNRIs) like venlafaxine. Mood stabilizers like lithium, valproate, carbamazepine, lamotrigine or topiramate are used as second line. Impulse control dyscontrol symptoms are self-mutilation, aggression, eroticism, reckless sex, extravagant spending and uncontrolled substance use. They are managed with SSRIs as first line and monoamine oxidase inhibitors (MAOIs) as second line [1]. British guidelines recommend against the use of medications for these symptoms [2]. Cognitive perceptual symptoms incorporate paranoia, delusions, hallucination, derealisation, depersonalization and suspiciousness. Low dose neuroleptics or antipsychotic medications are used. They help with psychotic symptoms as well as mood issues.